MXPA05008507A - Medicamento para enfermedad viral. - Google Patents

Medicamento para enfermedad viral.

Info

Publication number
MXPA05008507A
MXPA05008507A MXPA05008507A MXPA05008507A MXPA05008507A MX PA05008507 A MXPA05008507 A MX PA05008507A MX PA05008507 A MXPA05008507 A MX PA05008507A MX PA05008507 A MXPA05008507 A MX PA05008507A MX PA05008507 A MXPA05008507 A MX PA05008507A
Authority
MX
Mexico
Prior art keywords
remedy
hcv
viral disease
medicinal composition
preventive
Prior art date
Application number
MXPA05008507A
Other languages
English (en)
Inventor
Kenichi Kawasaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MXPA05008507A publication Critical patent/MXPA05008507A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se pretende proveer una composicion farmaceutica para prevenir o tratar infecciones virales; una composicion farmaceutica que contiene un compuesto que tiene una actividad anti-VHC muy potente y efectos inhibidores de la amplificacion del VHC, y muestra baja citotoxicidad in vivo, es muy util como un agente preventivo/terapeutico contra el VHC.
MXPA05008507A 2003-02-12 2004-02-12 Medicamento para enfermedad viral. MXPA05008507A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034056 2003-02-12
JP2003272420 2003-07-09
PCT/JP2004/001498 WO2004071503A1 (ja) 2003-02-12 2004-02-12 ウイルス治療薬

Publications (1)

Publication Number Publication Date
MXPA05008507A true MXPA05008507A (es) 2005-10-20

Family

ID=32871168

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008507A MXPA05008507A (es) 2003-02-12 2004-02-12 Medicamento para enfermedad viral.

Country Status (16)

Country Link
US (2) US7776918B2 (es)
EP (1) EP1593378B1 (es)
JP (1) JP3921227B2 (es)
KR (1) KR101071014B1 (es)
AU (1) AU2004211850B2 (es)
BR (1) BRPI0407140A (es)
CA (1) CA2515370C (es)
HK (1) HK1095036A1 (es)
IL (1) IL169551A (es)
MX (1) MXPA05008507A (es)
MY (1) MY141506A (es)
NO (1) NO20053348L (es)
NZ (1) NZ542250A (es)
RU (1) RU2350600C2 (es)
TW (1) TWI335219B (es)
WO (1) WO2004071503A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1819990B (zh) 2003-07-09 2010-04-21 中外制药株式会社 具有抗hcv作用的化合物及其制法
JP2006077004A (ja) * 2004-08-11 2006-03-23 Chugai Pharmaceut Co Ltd 抗ｈｃｖ作用を有する化合物およびそれを含む医薬組成物
JP4849622B2 (ja) * 2004-08-11 2012-01-11 中外製薬株式会社 Ｈｃｖ感染症を治療または予防するための薬剤
WO2006088071A1 (ja) * 2005-02-17 2006-08-24 Chugai Seiyaku Kabushiki Kaisha 抗ｈｃｖ作用を有する化合物の製造方法およびその中間体
WO2007000994A1 (ja) * 2005-06-28 2007-01-04 Chugai Seiyaku Kabushiki Kaisha 抗ｈｃｖ作用を有する化合物の製造方法
JPWO2007132882A1 (ja) 2006-05-16 2009-09-24 財団法人 東京都医学研究機構 Ｈｃｖ感染症を治療または予防するための医薬組成物
TW201010692A (en) * 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
JPWO2010061881A1 (ja) 2008-11-26 2012-04-26 中外製薬株式会社 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
JP2013121935A (ja) 2011-12-12 2013-06-20 Institute Of Microbial Chemistry 化合物、及び不斉合成反応
WO2014027696A1 (ja) 2012-08-17 2014-02-20 中外製薬株式会社 抗ｈｃｖ作用を有する経口投与可能なビリジオファンジン誘導体
JP5933867B1 (ja) * 2016-03-28 2016-06-15 公益財団法人微生物化学研究会 化合物、及び不斉合成反応
CN114105855B (zh) * 2020-08-31 2024-03-15 中国科学院大连化学物理研究所 一种在吲哚c2位引入异戊烯基的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364948A (en) * 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
EP0526936A3 (en) * 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
AU7552098A (en) * 1997-06-09 1998-12-30 Takara Shuzo Co., Ltd. Physiologically active substances tkr2449, process for producing the same, and microorganism

Also Published As

Publication number Publication date
JPWO2004071503A1 (ja) 2006-06-01
TW200501940A (en) 2005-01-16
MY141506A (en) 2010-05-14
NZ542250A (en) 2008-12-24
EP1593378A1 (en) 2005-11-09
JP3921227B2 (ja) 2007-05-30
AU2004211850A1 (en) 2004-08-26
WO2004071503A1 (ja) 2004-08-26
US20100274026A1 (en) 2010-10-28
KR101071014B1 (ko) 2011-10-06
US20060217434A1 (en) 2006-09-28
KR20050098929A (ko) 2005-10-12
US7776918B2 (en) 2010-08-17
NO20053348L (no) 2005-09-12
AU2004211850B2 (en) 2009-06-04
HK1095036A1 (en) 2007-04-20
NO20053348D0 (no) 2005-07-11
IL169551A (en) 2011-10-31
TWI335219B (en) 2011-01-01
EP1593378A4 (en) 2009-05-06
RU2005128297A (ru) 2006-02-27
EP1593378B1 (en) 2013-09-25
CA2515370C (en) 2012-01-17
CA2515370A1 (en) 2004-08-26
AU2004211850A2 (en) 2009-02-12
BRPI0407140A (pt) 2006-02-07
RU2350600C2 (ru) 2009-03-27

Similar Documents

Publication Publication Date Title
HK1108703A1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
DE60324552D1 (en) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
WO2006039488A3 (en) Hcv ns3-ns4a protease inhibition
AU2002360592A8 (en) Inhibitors of hepatitis c virus
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MY128463A (en) 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
EP2368900A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RS20110578A2 (en) MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
PL376409A1 (en) Composition for the treatment of infection by flaviviridae viruses
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
MY152824A (en) Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
TW200633995A (en) Andrographolide derivatives to treat viral infections
TW200633718A (en) Treatment of hepatitis c in the asian population
MXPA05008507A (es) Medicamento para enfermedad viral.
ZA200303037B (en) Herbal pharmaceutical composition for treatment of HIV/Aids patients.
MX2007008585A (es) Compuestos peptidicos.
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с

Legal Events

Date Code Title Description
FG Grant or registration